Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial

Geert A. Cirkel; Paul Hamberg; Stefan Sleijfer; Olaf J. L. Loosveld; M. Wouter Dercksen; Maartje Los; Marco B. Polee; Franchette van den Berkmortel; Maureen J. Aarts; Laurens V. Beerepoot; Gerard Groenewegen; Martijn P. Lolkema; Metin Tascilar; Johanna E. A. Portielje; Frank P. J. Peters; Heinz-Josef Kluempen; Vincent van der Noort; John B. A. G. Haanen; Emile E. Voest; Dutch WIN-O Consortium

doi:10.1001/jamaoncol.2016.5202

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial

Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, Olaf J. L. Loosveld, M. Wouter Dercksen, Maartje Los, Marco B. Polee, Franchette van den Berkmortel, Maureen J. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, Johanna E. A. Portielje, Frank P. J. Peters, Heinz-Josef Kluempen, Vincent van der Noort, John B. A. G. Haanen, Emile E. Voest^*, Dutch WIN-O Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	501-508
Number of pages	8
Journal	JAMA Oncology
Volume	3
Issue number	4
DOIs	https://doi.org/10.1001/jamaoncol.2016.5202
Publication status	Published - 1 Apr 2017

Keywords

PHASE-III TRIAL
SUNITINIB RECHALLENGE
DRUG-RESISTANCE
CARCINOMA
THERAPY
SURVEILLANCE
GUIDELINES
EFFICACY

Access to Document

10.1001/jamaoncol.2016.5202

Cite this

Cirkel, G. A., Hamberg, P., Sleijfer, S., Loosveld, O. J. L., Dercksen, M. W., Los, M., Polee, M. B., van den Berkmortel, F., Aarts, M. J., Beerepoot, L. V., Groenewegen, G., Lolkema, M. P., Tascilar, M., Portielje, J. E. A., Peters, F. P. J., Kluempen, H-J., van der Noort, V., Haanen, J. B. A. G., Voest, E. E., & Dutch WIN-O Consortium (2017). Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial. JAMA Oncology, 3(4), 501-508. https://doi.org/10.1001/jamaoncol.2016.5202

Cirkel, Geert A. ; Hamberg, Paul ; Sleijfer, Stefan ; Loosveld, Olaf J. L. ; Dercksen, M. Wouter ; Los, Maartje ; Polee, Marco B. ; van den Berkmortel, Franchette ; Aarts, Maureen J. ; Beerepoot, Laurens V. ; Groenewegen, Gerard ; Lolkema, Martijn P. ; Tascilar, Metin ; Portielje, Johanna E. A. ; Peters, Frank P. J. ; Kluempen, Heinz-Josef ; van der Noort, Vincent ; Haanen, John B. A. G. ; Voest, Emile E. ; Dutch WIN-O Consortium. / Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial. In: JAMA Oncology. 2017 ; Vol. 3, No. 4. pp. 501-508.

@article{35f3b666d9794bbcb40538f356068b2d,

title = "Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial",

keywords = "PHASE-III TRIAL, SUNITINIB RECHALLENGE, DRUG-RESISTANCE, CARCINOMA, THERAPY, SURVEILLANCE, GUIDELINES, EFFICACY",

author = "Cirkel, {Geert A.} and Paul Hamberg and Stefan Sleijfer and Loosveld, {Olaf J. L.} and Dercksen, {M. Wouter} and Maartje Los and Polee, {Marco B.} and {van den Berkmortel}, Franchette and Aarts, {Maureen J.} and Beerepoot, {Laurens V.} and Gerard Groenewegen and Lolkema, {Martijn P.} and Metin Tascilar and Portielje, {Johanna E. A.} and Peters, {Frank P. J.} and Heinz-Josef Kluempen and {van der Noort}, Vincent and Haanen, {John B. A. G.} and Voest, {Emile E.} and {Dutch WIN-O Consortium}",

year = "2017",

month = apr,

day = "1",

doi = "10.1001/jamaoncol.2016.5202",

language = "English",

volume = "3",

pages = "501--508",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "4",

}

Cirkel, GA, Hamberg, P, Sleijfer, S, Loosveld, OJL, Dercksen, MW, Los, M, Polee, MB, van den Berkmortel, F, Aarts, MJ, Beerepoot, LV, Groenewegen, G, Lolkema, MP, Tascilar, M, Portielje, JEA, Peters, FPJ, Kluempen, H-J, van der Noort, V, Haanen, JBAG, Voest, EE & Dutch WIN-O Consortium 2017, 'Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial', JAMA Oncology, vol. 3, no. 4, pp. 501-508. https://doi.org/10.1001/jamaoncol.2016.5202

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial. / Cirkel, Geert A.; Hamberg, Paul; Sleijfer, Stefan; Loosveld, Olaf J. L.; Dercksen, M. Wouter; Los, Maartje; Polee, Marco B.; van den Berkmortel, Franchette; Aarts, Maureen J.; Beerepoot, Laurens V.; Groenewegen, Gerard; Lolkema, Martijn P.; Tascilar, Metin; Portielje, Johanna E. A.; Peters, Frank P. J.; Kluempen, Heinz-Josef; van der Noort, Vincent; Haanen, John B. A. G.; Voest, Emile E.; Dutch WIN-O Consortium.

In: JAMA Oncology, Vol. 3, No. 4, 01.04.2017, p. 501-508.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial

AU - Cirkel, Geert A.

AU - Hamberg, Paul

AU - Sleijfer, Stefan

AU - Loosveld, Olaf J. L.

AU - Dercksen, M. Wouter

AU - Los, Maartje

AU - Polee, Marco B.

AU - van den Berkmortel, Franchette

AU - Aarts, Maureen J.

AU - Beerepoot, Laurens V.

AU - Groenewegen, Gerard

AU - Lolkema, Martijn P.

AU - Tascilar, Metin

AU - Portielje, Johanna E. A.

AU - Peters, Frank P. J.

AU - Kluempen, Heinz-Josef

AU - van der Noort, Vincent

AU - Haanen, John B. A. G.

AU - Voest, Emile E.

AU - Dutch WIN-O Consortium

PY - 2017/4/1

Y1 - 2017/4/1

KW - PHASE-III TRIAL

KW - SUNITINIB RECHALLENGE

KW - DRUG-RESISTANCE

KW - CARCINOMA

KW - THERAPY

KW - SURVEILLANCE

KW - GUIDELINES

KW - EFFICACY

U2 - 10.1001/jamaoncol.2016.5202

DO - 10.1001/jamaoncol.2016.5202

M3 - Article

C2 - 27918762

VL - 3

SP - 501

EP - 508

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 4

ER -